oral glp-1 drugs in development Emerging Trends the of Receptor Agonists GLP-1 Receptor Agonist Market Size

The second group included individuals who started and continued either a GLP-1 receptor agonist or SGLT-2 inhibitor for the first time between January 1, 2013, and December 31, 2020

*Fatal myocardial infarction

I then turned 65 yrs old and that is the age I had to switch to Tricare for life, with Medicare A and B which now TFL doesnt cover my Zepbound anymore

Diabetes Care 34(Supplement_2):S279-84 Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P et al (2019) Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Clinical trials extend to 72 weeks and beyond